A
Aleva Neurotherapeutics
Pioneered directional deep brain stimulation DBS in Neuromodulation treatment of Parkinson's disease and essential tremor
About Aleva Neurotherapeutics
Aleva Neurotherapeutics is a Swiss-based startup that specializes in the development and commercialization of Deep Brain Stimulation (DBS) technologies. Originating as a spin-off from the Swiss Federal Institute of Technology, the company's primary goal is to enhance the existing DBS treatment for patients suffering from neurological disorders. DBS is a medical procedure used to treat a variety of debilitating neurological symptoms—most commonly the debilitating symptoms of Parkinson’s disease, such as tremor, rigidity, stiffness, slowed movement, and walking problems.
Aleva has pioneered the directional mode of DBS, a more sophisticated technology that has set the industry standard for directional leads. This technology allows for more precise stimulation of specific areas of the brain, potentially reducing side effects and improving patient outcomes. The company holds 13 patent families and 90 granted patents in this area, demonstrating its expertise and commitment to innovation.
Aleva's business model revolves around partnering with leading neurological clinics in Europe, with plans to expand into worldwide markets in the near future. The company's revenue is generated through the sale of its directSTIM™ system, a DBS solution designed to eliminate surgical failures and non-responder patients. This system is fully manufactured and assembled in Switzerland, adhering to the highest quality standards.
In summary, Aleva Neurotherapeutics is a forward-thinking company dedicated to improving the lives of patients with neurological disorders through the development and commercialization of innovative DBS technologies.
Source: Dealroom company dataNews
Open roles
Aleva Neurotherapeutics in the Lausanne ecosystem
The Aleva Neurotherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
BioMedVC- BPBanexi Ventures Partners
Kreaxi
Series B and later5 investors entered at this stage
Fondation FIT
Integer HoldingsKinled Holding
- BVBB Biotech Ventures
- FCForrestal Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aleva Neurotherapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aleva Neurotherapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

